Drug Profile
HuABC 2
Alternative Names: HuABC2Latest Information Update: 19 Apr 2023
Price :
$50
*
At a glance
- Originator JN Biosciences
- Class Antibodies; Immunotherapies
- Mechanism of Action Interleukin 2 receptor beta subunit antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Immunological disorders
Most Recent Events
- 17 Apr 2023 Preclinical development is ongoing in USA (Parenteral) (JN Biosciences pipeline, April 2023)
- 28 Jun 2021 No recent reports of development identified for preclinical development in Immunological-disorders in USA (Parenteral)
- 23 May 2017 HuABC 2 is available for licensing as of 23 May 2017. http://jn-bio.com/pipeline/huabc2 (JN Biosciences pipeline, May 2017)